ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.585
      0.00%
      Bitcoin
      60,894.96
      0.16%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. HUTCHMED China Limited (HCM)

      7. HUTCHMED China Limited (HCM) News

      HCM

      HUTCHMED China (HCM)

      HUTCHMED China Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:HCM
      DateTimeSourceHeadlineSymbolCompany
      05/08/20244:30AMGlobeNewswire Inc.HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNASDAQ:HCMHUTCHMED China Limited
      04/26/20248:30AMGlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNASDAQ:HCMHUTCHMED China Limited
      04/05/20244:30AMGlobeNewswire Inc.HUTCHMED Highlights Data to be Presented at AACR Congress 2024NASDAQ:HCMHUTCHMED China Limited
      04/02/202412:30AMGlobeNewswire Inc.HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
      03/27/20248:00PMGlobeNewswire Inc.HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCNASDAQ:HCMHUTCHMED China Limited
      03/21/20248:00PMGlobeNewswire Inc.HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaNASDAQ:HCMHUTCHMED China Limited
      03/05/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      02/28/20246:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      02/28/20246:40AMEdgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:HCMHUTCHMED China Limited
      02/28/20246:30AMGlobeNewswire Inc.HUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesNASDAQ:HCMHUTCHMED China Limited
      02/07/20246:43AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      02/06/20247:00PMGlobeNewswire Inc.HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionNASDAQ:HCMHUTCHMED China Limited
      02/02/20246:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      02/02/20243:30AMGlobeNewswire Inc.HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipNASDAQ:HCMHUTCHMED China Limited
      02/01/20246:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      02/01/20243:30AMGlobeNewswire Inc.HUTCHMED to Announce 2023 Final ResultsNASDAQ:HCMHUTCHMED China Limited
      01/30/20246:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      01/29/202411:53PMGlobeNewswire Inc.HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerNASDAQ:HCMHUTCHMED China Limited
      01/11/20246:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      01/10/20247:00PMGlobeNewswire Inc.HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusNASDAQ:HCMHUTCHMED China Limited
      12/29/20236:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      12/21/20236:14AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      12/13/20236:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      12/12/202311:30PMGlobeNewswire Inc.HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current TermsNASDAQ:HCMHUTCHMED China Limited
      12/12/20237:00PMGlobeNewswire Inc.HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in ChinaNASDAQ:HCMHUTCHMED China Limited
      12/07/20236:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      12/01/20236:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      11/30/20237:00PMGlobeNewswire Inc.HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology CongressesNASDAQ:HCMHUTCHMED China Limited
      11/30/20236:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HCMHUTCHMED China Limited
      11/10/20238:35AMGlobeNewswire Inc.Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingNASDAQ:HCMHUTCHMED China Limited
       Showing the most relevant articles for your search:NASDAQ:HCM

      Your Recent History

      USOTC
      JKRO
      Jakroo (GM)
      BIT
      P1XX14
      NLBNPIT1XX14 20240620 16...
      Delayed Upgrade Clock